Apply for PatientOne Co-Pay Program
The outcome of the Phase 3 study of Lartruvo in combination with doxorubicin does not support initiating treatment of Lartruvo in patients with soft tissue sarcoma, outside of participation in a clinical trial. Therefore, Lilly PatientOne will only be accepting applications for existing or current Lartruvo patients who received at least one infusion of Lartruvo on or before January 25, 2019.
Apply online or download an application to complete and fax.
This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.